Pre-immunotherapy radiotherapy enhanced the efficacy of multi-line sintilimab in unresectable advanced esophageal squamous cell carcinoma.
Pre-immunotherapy radiotherapy enhanced the efficacy of multi-line sintilimab in unresectable advanced esophageal squamous cell carcinoma.
复制标题
DOI：
10.3389/fimmu.2023.960339
复制
发表时间：
2023
影响因子：
7.3
通讯作者：
Zhu, Hui
中科院分区：
文献类型：
--
作者：
Xu, Shuhui;Xu, Xianxing;Zhu, Hui
免疫治疗在食管鳞状细胞癌（ESCC）治疗中的应用逐渐增多。在这项回顾性研究中，我们评估了多线sintiliumab治疗不可切除的晚期ESCC的疗效并探讨了潜在的预后因素。所有病理标本均来自我院病理科。我们对133例患者的手术或穿刺标本进行了PD-L1免疫组化染色。我们评估了多线sintilimab的疗效，并根据多变量分析找到了潜在的因素。我们评估了放疗和免疫治疗的关系，并根据患者在免疫治疗前3个月内是否接受过放疗，我们试图分析无进展生存期（PFS）和总生存期（OS）的差异。本回顾性研究于2019年1月至2021年12月期间共入组133例患者。中位随访时间为16.1个月。所有患者均接受至少两个周期的sintiliumab治疗。在所有患者中，共有74例发生疾病进展，中位无进展生存期为9.0个月（95% CI 7.701-10.299）。我们发现，免疫治疗前放疗是影响多线sintiliumab预后的一个可能的预测因素，3个月是一个重要的截止时间。共有128例患者（96.2%）在免疫治疗前接受了放疗。在这些患者中，89例（66.9%）在免疫治疗前3个月内接受过放射治疗。在放疗前3个月内接受治疗的患者的PFS显著长于在免疫治疗前3个月内未接受放疗的患者（中位无进展生存期10.0个月[95% CI 8.030-11.970] vs. 5.0个月[95% CI 2.755-7.245]）。在所有患者中，中位总生存期为14.9个月（95%CI 12.558-17.242）。在免疫治疗前3个月内接受过放疗的患者的总生存期显著长于未接受过放疗的患者（中位总生存期15.3个月[95% CI 13.724-16.876] vs. 12.2个月[10.001-14.399]）。基于这项回顾性研究，sintiliumab是既往接受过治疗的不可切除晚期ESCC患者的重要选择，3个月内的免疫治疗前放疗增强了疗效。
The use of immunotherapy for the treatment of esophageal squamous cell carcinoma (ESCC) is gradually increasing. In this retrospective study, we evaluated the efficacy and explored potential factors of prognosis in multi-line sintilimab for unresectable advanced ESCC. All pathological specimens were available from our Department of Pathology. We performed PD-L1 immunohistochemical staining of surgical or puncture specimens from 133 patients. We evaluated the efficacy of multi-line sintilimab and found potential factors according to multivariate analysis. We assessed the relationship between radiotherapy and immunotherapy, and according to whether patients had received radiotherapy within 3 months prior to immunotherapy, we attempted to analyze differences in progression-free survival (PFS) and overall survival (OS). A total of 133 patients were enrolled in this retrospective study between January 2019 and December 2021. The median follow-up was 16.1 months. All patients were treated with at least two cycles of sintilimab. Of all patients, a total of 74 experienced disease progression, with a median progression-free survival of 9.0 months (95% CI 7.701–10.299). We found that pre-immunotherapy radiotherapy was a possible predictor that affected the prognosis of multi-line sintilimab and that 3 months was a significant cutoff. A total of 128 patients (96.2%) had received radiotherapy prior to immunotherapy. Of those patients, 89 (66.9%) had received radiation therapy within 3 months prior to immunotherapy. PFS was considerably longer in patients who were treated within 3 months of radiotherapy than in patients who did not receive radiation therapy within 3 months of radiation therapy prior to immunotherapy (median progression-free survival 10.0 months [95% CI 8.030–11.970] vs. 5.0 months [95% CI 2.755–7.245]). Among all patients, the median overall survival was 14.9 months (95% CI 12.558–17.242). Overall survival was significantly longer in patients who had previously received radiotherapy within 3 months prior to immunotherapy than in those who had not (median overall survival 15.3 months [95% CI 13.724–16.876] vs. 12.2 months [10.001–14.399]. Based on this retrospective study, sintilimab is a significant option for patients with unresectable advanced ESCC who have been previously treated, and pre-immunotherapy radiotherapy within 3 months enhanced the efficacy.
登录
查看更多内容
PD-1和PD-L1检查点信号传导抑制癌症免疫疗法：机制，组合和临床结果。
影响因子：
5.6
作者：
Alsaab HO;Sau S;Alzhrani R;Tatiparti K;Bhise K;Kashaw SK;Iyer AK
通讯作者：
Iyer AK
影响因子：
7.3
作者：
Van Cutsem, E.;Kato, K.;Ajani, J.;Shen, L.;Xia, T.;Ding, N.;Zhan, L.;Barnes, G.;Kim, S-B
通讯作者：
Kim, S-B
放疗加卡瑞利珠单抗治疗局部晚期食管鳞状细胞癌的安全性和可行性
DOI：
10.1002/onco.13797
发表时间：
2021-07
期刊：
The oncologist
影响因子：
--
作者：
Zhang W;Yan C;Gao X;Li X;Cao F;Zhao G;Zhao J;Er P;Zhang T;Chen X;Wang Y;Jiang Y;Wang Q;Zhang B;Qian D;Wang J;Zhou D;Ren X;Yu Z;Zhao L;Yuan Z;Wang P;Pang Q
通讯作者：
Pang Q
影响因子：
--
作者：
Zhang Z;Hong ZN;Xie S;Lin W;Lin Y;Zhu J;Yang X;Lin Z;Lin J;Kang M
通讯作者：
Kang M
影响因子：
51.1
作者：
Kato, Ken;Cho, Byoung Chul;Kitagawa, Yuko
通讯作者：
Kitagawa, Yuko